AstraZeneca Pharma India Ltd - 506820 - Disclosure Of Related Party Transactions
Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended March 31, 2021 for your information and records. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Of Related Party Transactions
Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended March 31, 2021 for your information and records.
AstraZeneca vax 2nd dose FAQs about blood clots, safety, risks and symptoms
Rare but serious blood clots that have been linked the AstraZeneca Covid-19 vaccine have many people especially those who have already had one dose of the vaccine looking for information
Serum Institute to raise AstraZeneca COVID-19 vaccine output in June
Owing to vaccine shortage, in March, India had put a temporary hold on all major exports of the AstraZeneca coronavirus vaccine to meet demand at home as infections rise.
Chinese vaccine to cost Bangladesh double of India's Oxford-AstraZeneca
The Bangladesh government has approved the purchase of 15 million Covid-19 vaccine doses from China. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard and Prajavani newspapers.
AstraZeneca Pharma, Abbott Healthcare terminate distribution agreements for diabetes drug in India
"AstraZeneca India and Abbott have mutually terminated the distribution agreement on May 27, 2021," AstraZeneca India said in a regulatory filing. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Termination Of Distribution Agreement Between Astrazeneca Pharma India Limited And Abbott Healthcare Private Limited
We refer to our announcement of December 7, 2018, wherein we had informed about the Distribution Agreement entered into between AstraZeneca Pharma India Limited (AstraZeneca India) and Abbott Healthcare Private Limited (Abbott) for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. Under the said agreement, Abbott promoted and distributed Dapagliflozin under the brand name 'Gledepa' and the combination of Dapagliflozin with Metformin under the brand name 'Gledepa Met'. Please note that by virtue of the said Distribution Agreement, Abbott had not been conferred with any license to the patents over the drugs comprising Dapagliflozin, and the license granted to Abbott was with respect only to the use of the trademarks 'Gledepa' and 'Gledepa Met' We now wish to further update that AstraZeneca India and Abbott have mutually terminated the Distribution Agreement on 27th May 2021. Copy of complete intimation is enclosed for reference. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Change In Business Relationship And Discontinuation Of The Distribution Services Under The Terms Of The Distribution Agreement Between Astrazeneca Pharma India Limited & Sun Pharma Laboratories Limited For Dapagliflozin And Its Combinations In India
We refer to our announcement of March 23, 2016, wherein we had informed about the Distribution Services Agreement entered into between AstraZeneca Pharma India Limited (AstraZeneca India) and Sun Pharma Laboratories Limited (Sun Pharma) for the distribution of Dapagliflozin, an innovative Type 2 diabetes medicine, in India. AstraZeneca India and Sun Pharma have discontinued its existing Distribution Services Agreement signed in 2016 by entering into a Transition Supply Agreement with effect from 28th May 2021. Under the Transition Supply Agreement, Sun Pharma will continue to promote and distribute Dapagliflozin and the combinations of Dapagliflozin with Metformin under the brand Oxra and Oxramet until such period of time as mutually agreed between the parties, post which all supplies to Sun Pharma from AstraZeneca India shall cease. Copy of complete intimation is enclosed for reference.AstraZeneca, Sputnik makers respond to Telangana vaccine tender
Telangana has called for global tenders for supply of one crore doses. The tender process, which began on May 21, will close on June 4